On August !, 2013, BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) disclosed in a regulatory filing that on July 31, the company was notified by the United States Food and Drug Administration (FDA) that the agency lifted the clinical hold placed on its hereditary angioedema (NYSE:HAE) drug BCX 4161. The FDA notified BioCryst that the complete response letter (NYSE:CRL) submitted by BioCryst in response to the hold satisfactorily addressed its concerns. BioCryst can now conduct clinical trials in the United States to further the development of BCX 4161. BioCryst stock was up over 20% after the news.
On July 30-31, BioCryst announced to sell up to 4 million shares of stock at $4.40 per share to raise...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|